Citations (65)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Mohammad Ma'koseh, Hebah Farfoura, Alaa Abufara, Reem Elmusa, Ahmad Hushki, Nour Faqeer, Hamza Ghatasheh, Omar Shahin, Tala Alawabdeh, Mohammad Al-Rwashdeh, Khalid Halahleh, Akram Al-Ibraheem & Kamal Alrabi. (2023) Outcome and patterns of relapse in primary gastric diffuse large B cell lymphoma treated with RCHOP. Hematology 28:1.
Read now
Read now
Kim Oren Gradel, Thomas Stauffer Larsen, Henrik Frederiksen, Pernille Just Vinholt, Maria Iachina, Pedro Póvoa, Fernando Godinho Zampieri, Stig Lønberg Nielsen, Ram Benny Dessau, Jens Kjølseth Møller, Thøger Gorm Jensen, Ming Chen, John Eugenio Coia & Jelena Jelicic. (2022) Impact of C-reactive protein and albumin levels on short, medium, and long term mortality in patients with diffuse large B-cell lymphoma. Annals of Medicine 54:1, pages 713-722.
Read now
Read now
Lasse Hjort Jakobsen, Jorne Lionel Biccler, Peter de Nully Brown, Judit Mészáros Jørgensen, Pär Lars Josefsson, Christian Bjørn Poulsen, Jørn Starklint, Michael Roost Clausen, Per Trøllund Pedersen, Maja Bech Juul, Marianne Tang Severinsen, Martin Bøgsted & Tarec Christoffer El-Galaly. (2019) No differential overall or relative survival effect of rituximab in male and female patients with diffuse large B-cell lymphoma: a Danish population-based study of 3783 patients. Leukemia & Lymphoma 60:11, pages 2798-2801.
Read now
Read now
David A. Bond, Ying Huang, Amy S. Ruppert, Alison R. Walker, Emily K. Dotson, Julianna Roddy, Kristie A. Blum & Beth A. Christian. (2017) Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose. Leukemia & Lymphoma 58:7, pages 1589-1597.
Read now
Read now
Muhammad Sharif Hasni, Mattias Berglund, Konstantin Yakimchuk, Jiyu Guan, Johan Linderoth, Rose Marie Amini, Gunilla Enblad & Sam Okret. (2017) Estrogen receptor β1 in diffuse large B-cell lymphoma growth and as a prognostic biomarker. Leukemia & Lymphoma 58:2, pages 418-427.
Read now
Read now
Anne O. Gang, Michael Pedersen, Francesco d’Amore, Lars M. Pedersen, Bo A. Jensen, Paw Jensen, Michael B. Møller, Hans T. Mourits-Andersen, Robert S. Pedersen, Tobias W. Klausen & Peter de N. Brown. (2015) A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry. Leukemia & Lymphoma 56:9, pages 2556-2562.
Read now
Read now
Rita Coutinho & John Gribben. (2013) Biomarkers of diffuse large B-cell lymphoma: impact on diagnosis, treatment, and prognosis. Current Biomarker Findings 3, pages 17-34.
Read now
Read now
Hiroshi Arima, Hayato Maruoka, Koji Nasu, Sumie Tabata, Masayuki Kurata, Akiko Matsushita, Yukihiro Imai, Takayuki Takahashi & Takayuki Ishikawa. (2013) Impact of occult bone marrow involvement on the outcome of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone therapy for diffuse large B-cell lymphoma. Leukemia & Lymphoma 54:12, pages 2645-2653.
Read now
Read now
Angelo M. Carella, Carmino A. de Souza, Stefano Luminari, Luigi Marcheselli, Annalisa Chiappella, Alice di Rocco, Marina Cesaretti, Andrea Rossi, Luigi Rigacci, Gianluca Gaidano, Francesco Merli, Michele Spina, Caterina Stelitano, Stefan Hohaus, Anna Barbui, Benedetta Puccini, Eliana C. Miranda, Annalisa Guida & Massimo Federico. (2013) Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study. Leukemia & Lymphoma 54:1, pages 53-57.
Read now
Read now
Liang Wang, Panpan Liu, Qirong Geng, Xiaoqin Chen & Yue Lv. (2011) Prognostic significance of neuron-specific enolase in patients with diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapy. Leukemia & Lymphoma 52:9, pages 1697-1703.
Read now
Read now
Dai Chihara, Yasuhiro Oki, Shouji Ine, Kazuhito Yamamoto, Harumi Kato, Hirofumi Taji, Yoshitoyo Kagami, Yasushi Yatabe, Shigeo Nakamura & Yasuo Morishima. (2009) Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy. Leukemia & Lymphoma 50:12, pages 1999-2004.
Read now
Read now
Alessandro Pavan, Michele Spina, Vincenzo Canzonieri, Silvia Sansonno, Giuseppe Toffoli & Valli De Re. (2008) Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-κB pathway as a target for new therapeutic strategies. Leukemia & Lymphoma 49:11, pages 2048-2058.
Read now
Read now
Articles from other publishers (53)
B Sağlam, M Albayrak, A Yıldız, P Tığlıoğlu, M Tığlıoğlu, MR Aras, F Yılmaz, S Maral & HBA Öztürk. (2023) The Prognostic Impact of Comorbidity, Nutritional and Performance Status on Patients with Diffuse Large B Cell Lymphoma. Nigerian Journal of Clinical Practice 26:10, pages 1512-1518.
Crossref
Crossref
Nathalie Lehnen & Michael Hallek. (2023) Geschlechtsspezifische Unterschiede spezieller TumorerkrankungenSex-specific differences of special tumor diseases. Die Innere Medizin 64:8, pages 717-726.
Crossref
Crossref
Jason Yongsheng Chan, Nagavalli Somasundaram, Nicholas Grigoropoulos, Francesca Lim, Michelle Limei Poon, Anand Jeyasekharan, Kheng Wei Yeoh, Daryl Tan, Georg Lenz, Choon Kiat Ong & Soon Thye Lim. (2023) Evolving therapeutic landscape of diffuse large B-cell lymphoma: challenges and aspirations. Discover Oncology 14:1.
Crossref
Crossref
Yanyan Lu, Hong Zhu, Yang Liu, Ying Wang, Yinxiang Sun, Hai Cheng, Zhiling Yan, Jiang Cao, Wei Sang, Feng Zhu, Depeng Li, Haiying Sun, Junnian Zheng, Kailin Xu & Zhenyu Li. (2023) Prognostic value of prelymphodepletion absolute lymphocyte counts in relapsed/refractory diffuse large B-cell lymphoma patients treated with chimeric antigen receptor T cells. Frontiers in Immunology 14.
Crossref
Crossref
Han Zhao, Rongqiu Liu, Yu Tao, Luca Bertero, Lizhi Feng, Bo Liu, Zhimin Chen, Jialong Guan, Baolin Liao, Linghua Li, Haolan He & Hua You. (2023) Construction and validation of prognostic scoring models to risk stratify patients with acquired immune deficiency syndrome‐related diffuse large B cell lymphoma. Journal of Medical Virology 95:5.
Crossref
Crossref
Ali Gholami, Khosro Farhadi, Fatemeh Sayyadipour, Masoud Soleimani & Fakhredin Saba. (2022) Long noncoding RNAs (lncRNAs) in human lymphomas. Genes & Diseases 9:4, pages 900-914.
Crossref
Crossref
Shama Jaswal, Vanessa Sanders, Priyanka Pullarkat, Stephanie Teja, Amber Salter, Marcus P. Watkins, Norman Atagu, Daniel R. Ludwig, Joyce Mhlanga, Vincent M. Mellnick, Linda R. Peterson, Nancy L. Bartlett, Brad S. Kahl, Todd A. Fehniger, Armin Ghobadi, Amanda F. Cashen, Neha Mehta-Shah & Joseph E. Ippolito. (2022) Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma. Cancers 14:12, pages 2932.
Crossref
Crossref
Müjde Durmaz, Otto Visser, Eduardus F. M. Posthuma, Rolf E. Brouwer, Djamila E. Issa, Daphne de Jong, King H. Lam, Nicole M. A. Blijlevens, Josée M. Zijlstra, Martine E. D. Chamuleau, Pieternella J. Lugtenburg, Marie José Kersten & Avinash G. Dinmohamed. (2022) Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018. Blood Cancer Journal 12:3.
Crossref
Crossref
Tzer-Ming Chuang, Yi-Chang Liu, Hui-Hua Hsiao, Hui-Ching Wang, Jeng-Shiun Du, Tsung-Jang Yeh, Yuh-Ching Gau, Ya-Lun Ke, Ching-I Yang, Ching-Ping Lee, Chin-Mu Hsu & Shih-Feng Cho. (2021) Low Geriatric Nutritional Risk Index Is Associated with Poorer Prognosis in Elderly Diffuse Large B-Cell Lymphoma Patients Unfit for Intensive Anthracycline-Containing Therapy: A Real-World Study. Nutrients 13:9, pages 3243.
Crossref
Crossref
Zheng-Huan Liu, Lu-Chen Yang, Pan Song, Kun Fang, Jing Zhou, Zhu-Feng Peng & Qiang Dong. (2021) Primary Diffuse Large B-Cell Lymphoma of the Urinary Tract: A Population-Based Analysis. Frontiers in Oncology 11.
Crossref
Crossref
Lasse Hjort Jakobsen, Torbjörn Callréus, Maurizio Sessa, Mats Jerkeman, Morten Andersen & Tarec Christoffer El‐Galaly. (2021)
Detecting deviations from the efficacy and safety results of single‐arm trials using real‐world data: The case of a
CAR‐T
cell therapy in B‐cell lymphoma
. Pharmacoepidemiology and Drug Safety 30:4, pages 514-519.
Crossref
Crossref
ChandranK Nair, AnjuR Kurup, A Manuprasad, PraveenKumar Shenoy & Vineetha Raghavan. (2021) Pattern of extranodal involvement and its impact on survival in diffuse large B-cell lymphoma from a tertiary cancer center in rural India. Journal of Cancer Research and Therapeutics 17:4, pages 938.
Crossref
Crossref
Jialin Ma, Zheng Yan, Jiuyang Zhang, Wenping Zhou, Zhihua Yao, Haiying Wang, Junfeng Chu, Shuna Yao, Shuang Zhao, Peipei Zhang, Yuanlin Xu, Qingxin Xia, Jie Ma, Bing Wei, Shujun Yang, Kangdong Liu, Yongjun Guo & Yanyan Liu. (2020) A genetic predictive model for precision treatment of diffuse large B-cell lymphoma with early progression. Biomarker Research 8:1.
Crossref
Crossref
Jennifer L. Crombie & Philippe Armand. (2020) Diffuse Large B-Cell Lymphoma’s New Genomics: The Bridge and the Chasm. Journal of Clinical Oncology 38:30, pages 3565-3574.
Crossref
Crossref
Wen‐Chi Chou, Hung Chang, Po‐Nan Wang, Ming‐Chung Kuo, Jin‐Hou Wu, Tung‐Liang Lin, Yi‐Jiun Su, Hsiao‐Wen Kao, Che‐Wei Ou, Chia‐Yen Hung, Shun‐Wen Hsueh & Yu‐Shin Hung. (2020) Application of comprehensive geriatric assessment in predicting early mortality among elder patients with B‐cell lymphoma receiving immunochemotherapy. European Journal of Haematology 105:4, pages 399-407.
Crossref
Crossref
Xuejiao Yin, Lei Chen, Fengjuan Fan, Han Yan, Yuyang Zhang, Zhenli Huang, Chunyan Sun & Yu Hu. (2020) Trends in Incidence and Mortality of Waldenström Macroglobulinemia: A Population-Based Study. Frontiers in Oncology 10.
Crossref
Crossref
Yongqiang Wei, Xiaolei Wei, Weimin Huang, Jialin Song, Jingxia Zheng, Hong Zeng, Jianbo Liu, Minglang Zhan, Qi Wei & Ru Feng. (2020) Albumin improves stratification in the low IPI risk patients with diffuse large B-cell lymphoma. International Journal of Hematology 111:5, pages 681-685.
Crossref
Crossref
Sung-Won Kim, Yoshitaka Asakura, Kinuko Tajima, Toshiki Iwai, Hirofumi Taji, Takaaki Chou, Yasuo Morishima, Junji Suzumiya, Hisashi Sakamaki, Ritsuro Suzuki & Takahiro Fukuda. (2019) RETRACTED ARTICLE: High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey. International Journal of Hematology 111:2, pages 256-266.
Crossref
Crossref
Xuejiao Yin, Aoshuang Xu, Fengjuan Fan, Zhenli Huang, Qianwen Cheng, Lu Zhang, Chunyan Sun & Yu Hu. (2019) Incidence and Mortality Trends and Risk Prediction Nomogram for Extranodal Diffuse Large B-Cell Lymphoma: An Analysis of the Surveillance, Epidemiology, and End Results Database. Frontiers in Oncology 9.
Crossref
Crossref
Anshul Gupta, Prabhakar Mishra & Soniya Nityanand. (2021) Serum Albumin Predicts Survival in Indian Adult Diffuse Large B cell Lymphoma Patients in the Rituximab Era. Indian Journal of Medical and Paediatric Oncology 40:02, pages 232-239.
Crossref
Crossref
Huai-Hsuan HuangFei-Yuan HsiaoLi-Ju ChenHo-Min ChenBor-Sheng Ko. (2019) Women with Diffuse Large B Cell Lymphoma Benefit More from Rituximab-Containing Chemotherapy. Journal of Women's Health 28:2, pages 203-211.
Crossref
Crossref
Luis Ernesto Cuellar, Andrea Anampa-Guzmán, Alexis Manuel Holguín, Juan Velarde, Diana Portillo-Alvarez, Marco Antonio Zuñiga-Ninaquispe, Esther Rosa Luna-Reyes, Jule Vásquez, Joanne Marie Jeter & Karen Marie Winkfield. (2018) Prognostic factors in HIV-positive patients with non-Hodgkin lymphoma: a Peruvian experience. Infectious Agents and Cancer 13:1.
Crossref
Crossref
Yusuke Kanemasa, Tatsu Shimoyama, Yuki Sasaki, Tsunekazu Hishima & Yasushi Omuro. (2018) Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma. Annals of Hematology 97:6, pages 999-1007.
Crossref
Crossref
TingBo Liu, LiHong Chen, Jie Pan, LiLi Pan, JianDa Hu & ZhongYou Ji. (2018) Retrospective Analysis of a New Prognostic Score for Diffuse Large B-Cell Lymphoma Based on Interim Positron Emission Tomography-Computed Tomography. Acta Haematologica 139:3, pages 148-157.
Crossref
Crossref
Nicola Lehners, Isabelle Krämer, Maral Saadati, Axel Benner, Anthony D. Ho & Mathias Witzens-Harig. (2017) Analysis of prognostic factors in patients with newly diagnosed diffuse large B-cell lymphoma and skeletal involvement. BMC Cancer 17:1.
Crossref
Crossref
Daisuke Katoh, Yotaro Ochi, Tomohiro Yabushita, Yuichiro Ono, Nobuhiro Hiramoto, Satoshi Yoshioka, Noboru Yonetani, Akiko Matsushita, Hisako Hashimoto, Shuichiro Kaji, Yukihiro Imai & Takayuki Ishikawa. (2017) Peripheral Blood Lymphocyte-to-Monocyte Ratio at Relapse Predicts Outcome for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma in the Rituximab Era. Clinical Lymphoma Myeloma and Leukemia 17:12, pages e91-e97.
Crossref
Crossref
Samo Rozman, Iztok Grabnar, Srdjan Novaković, Ales Mrhar & Barbara Jezeršek Novaković. (2017) Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. British Journal of Clinical Pharmacology 83:8, pages 1782-1790.
Crossref
Crossref
Rocío Gutiérrez-Cívicos, Ana M. Hurtado, Daniel Torres-Moreno, José J. Sanchez-Blanco, Ignacio Español, Luciano Consuegra-Sánchez, Elena Perez-Ceballos, María D. Gutiérrez-Meca, Andrés Jerez & Pablo Conesa-Zamora. (2017) Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger. Pharmacogenetics and Genomics 27:2, pages 70-77.
Crossref
Crossref
Jeongkuk SeoWon Seog KimJin Seok KimSeok Jin KimJae Hoon LeeJun Shik HongGyeong-Won LeeSung Yong OhJi-Hyun LeeDok Hyun YoonWon-Sik LeeHyo Jung KimJae-Yong KwakHye Jin KangJae-Cheol JoYong ParkHo Sup LeeHyo-Jin KimCheolwon Suh. (2017) Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial. Blood Research 52:3, pages 200.
Crossref
Crossref
Osnat Bairey, Adi Shacham-Abulafia, Ofer Shpilberg & Ronit Gurion. (2016) Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor. Hematological Oncology 34:4, pages 184-192.
Crossref
Crossref
Raymond Boon Tar Lim, En Yun Loy, Gek Hsiang Lim, Huili Zheng, Khuan Yew Chow & Soon Thye Lim. (2015) Gender and ethnic differences in incidence and survival of lymphoid neoplasm subtypes in an Asian population: Secular trends of a population-based cancer registry from 1998 to 2012. International Journal of Cancer 137:11, pages 2674-2687.
Crossref
Crossref
Zhiyu Liu, Zijun Y Xu-Monette, Xin Cao, Ganiraju C Manyam, Xiaoxiao Wang, Alexandar Tzankov, Yi Xia, Xin Li, Carlo Visco, Ruifang Sun, Li Zhang, Santiago Montes-Moreno, Karen Dybkær, April Chiu, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L Richards, Eric D Hsi, William WL Choi, J Han van Krieken, Jooryung Huh, Maurilio Ponzoni, Andrés JM Ferreri, Ben M Parsons, Michael B Møller, Miguel A Piris, Jane N Winter, Dennis P O'Malley, L Jeffrey Medeiros & Ken H Young. (2015) Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy. Modern Pathology 28:10, pages 1297-1314.
Crossref
Crossref
Yi-Yang Chen, Cih-En Huang, Fu-Wen Liang, Chang-Hsien Lu, Pin-Tsung Chen, Kuan-Der Lee & Chih-Cheng Chen. (2015) Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index. Cancer Epidemiology 39:3, pages 382-387.
Crossref
Crossref
H R Junlén, S Peterson, E Kimby, S Lockmer, O Lindén, H Nilsson-Ehle, M Erlanson, H Hagberg, A Rådlund, O Hagberg & B E Wahlin. (2014) Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study. Leukemia 29:3, pages 668-676.
Crossref
Crossref
Jennifer Eatrides, Zachary Thompson, Ji-Hyun Lee, Celeste Bello & Samir Dalia. (2014) Serum albumin as a stable predictor of prognosis during initial treatment in patients with diffuse large B cell lymphoma. Annals of Hematology 94:2, pages 357-358.
Crossref
Crossref
Samir Dalia, Julio Chavez, Bryan Little, Celeste Bello, Kate Fisher, Ji-Hyun Lee, Paul Chervenick, Lubomir Sokol, Eduardo Sotomayor & Bijal Shah. (2014) Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Annals of Hematology 93:8, pages 1305-1312.
Crossref
Crossref
Gin Gin Gan, Rajaletchumy Subramaniam, Ping Chong Bee, Edmund Fui Min Chin, Habibah Abdul-Halim & Mei Chee Tai. (2014) Impact of Inadequate Doses of Rituximab in the Treatment of Diffuse Large B Cell Lymphoma in Malaysian Patients. Asian Pacific Journal of Cancer Prevention 15:4, pages 1703-1706.
Crossref
Crossref
Thomas M. Habermann. (2014) Is rituximab one for all ages and each sex?. Blood 123:5, pages 602-603.
Crossref
Crossref
Michael PfreundschuhCarsten MüllerSamira Zeynalova, Evelyn KuhntMartin H. J. WiesenGerhard HeldTanja RixeckerViola PoeschelCarsten ZwickMarcel Reiser, Norbert Schmitz & Niels Murawski. (2014) Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood 123:5, pages 640-646.
Crossref
Crossref
Clémentine Sarkozy, Nicolas Mounier, Alain Delmer, Achiel Van Hoof, Jean Michel Karsenti, Emmanuel Fleck, Marie Maerevoet, Jean Claude Eisenmann, Richard Delarue, Michel Fabbro & Bertrand Coiffier. (2014) Impact of BMI and Gender on Outcomes in DLBCL Patients Treated with R-CHOP: A Pooled Study from the LYSA. Lymphoma 2014, pages 1-12.
Crossref
Crossref
Murat Ozbalak, M. Cem Ar, Nukhet Tuzuner, Ayse Salihoglu, A. Emre Eskazan, Seniz Ongoren Aydin, Zafer Baslar, Teoman Soysal, Yildiz Aydin, Anil Barak Dolgun, Onder Ergonul & Burhan Ferhanoglu. (2013) Detailed Analysis of Diffuse Large B Cell Lymphoma Patients: A Single-Center, Retrospective Study. ISRN Hematology 2013, pages 1-9.
Crossref
Crossref
Francesco d'AmoreThomas RelanderGrete F. LauritzsenEsa JantunenHans HagbergHarald AndersonHarald HolteAnders ÖsterborgMats MerupPeter BrownOuti KuittinenMartin ErlansonBjørn ØstenstadUnn-Merete FagerliOle V. GadebergChrister SundströmJan DelabieElisabeth RalfkiaerMartine VornanenHelle E. Toldbod. (2012) Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01. Journal of Clinical Oncology 30:25, pages 3093-3099.
Crossref
Crossref
Ying-Jie Zhu, Jia-Jia Huang, Yi Xia, Wei Zhao, Wen-Qi Jiang, Tong-Yu Lin, Hui-Qiang Huang & Zhi-Ming Li. (2011) Primary mediastinal large B-cell lymphoma (PMLBCL) in Chinese patients: clinical characteristics and prognostic factors. International Journal of Hematology 94:2, pages 178-184.
Crossref
Crossref
Frédéric Peyrade, Fabrice Jardin, Catherine Thieblemont, Antoine Thyss, Jean-François Emile, Sylvie Castaigne, Bertrand Coiffier, Corinne Haioun, Serge Bologna, Olivier Fitoussi, Gérard Lepeu, Christophe Fruchart, Dominique Bordessoule, Michel Blanc, Richard Delarue, Maud Janvier, Bruno Salles, Marc André, Marion Fournier, Philippe Gaulard & Hervé Tilly. (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. The Lancet Oncology 12:5, pages 460-468.
Crossref
Crossref
WM Tai, PL Tang, YX Koo, X Hou, KW Tay, R Quek, M Tao & ST Lim. (2011) Do We Have the Right Prognostic Index for Diffuse Large B Cell Lymphoma (DLBCL) in the Era of Rituximab?. Proceedings of Singapore Healthcare 20:1, pages 48-54.
Crossref
Crossref
Sari Riihij?rvi, Minna Taskinen, Mats Jerkeman & Sirpa Lepp?. (2011) Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy*. European Journal of Haematology 86:2, pages 124-128.
Crossref
Crossref
Francesco Gaudio, Annamaria Giordano, Tommasina Perrone, Domenico Pastore, Paola Curci, Mario Delia, Anna Napoli, Clara de’ Risi, Alessandro Spina, Rosalia Ricco, Vincenzo Liso & Giorgina Specchia. (2011) High Ki67 Index and Bulky Disease Remain Significant Adverse Prognostic Factors in Patients with Diffuse Large B Cell Lymphoma before and after the Introduction of Rituximab. Acta Haematologica 126:1, pages 44-51.
Crossref
Crossref
Dai Chihara, Yasuhiro Oki, Shouji Ine, Harumi Kato, Hiroshi Onoda, Hirofumi Taji, Yoshitoyo Kagami, Kazuhito Yamamoto & Yasuo Morishima. (2010) Primary gastric diffuse large B‐cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG‐PET scan. European Journal of Haematology 84:6, pages 493-498.
Crossref
Crossref
Changhoon YooShin KimByeong Seok SohnJeong-Eun KimDok Hyun YoonJooryung HuhDae Ho LeeSang-We KimJung-Shin LeeCheolwon Suh. (2010) Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma. The Korean Journal of Internal Medicine 25:3, pages 301.
Crossref
Crossref
Nikolaos S. Salemis, Stavros Gourgiotis, Evangelos Tsiambas, Grigorios Karagkiouzis, Georgios Nakos & Vasilios Karathanasis. (2009) Diffuse Large B Cell Lymphoma of the Mesentery: An Unusual Presentation and Review of the Literature. Journal of Gastrointestinal Cancer 40:3-4, pages 79-82.
Crossref
Crossref
Gillianne Geet Yi Lai, Soon‐Thye Lim, Miriam Tao, Alexandre Chan, Huihua Li & Richard Quek. (2009) Late‐onset neutropenia following RCHOP chemotherapy in diffuse large B‐cell lymphoma. American Journal of Hematology 84:7, pages 414-417.
Crossref
Crossref
Kiriko Wada, Kunihiko Maeda, Katsushi Tajima, Takeo Kato, Tetsuji Kobata & Mitsunori Yamakawa. (2009) Expression of BAFF-R and TACI in reactive lymphoid tissues and B-cell lymphomas. Histopathology 54:2, pages 221-232.
Crossref
Crossref
. (2008) Current Awareness in Hematological Oncology. Hematological Oncology 26:3, pages 184-191.
Crossref
Crossref